Summary
The pharmacology of celiprolol and its relationship to some other beta-adrenoceptor antagonists is described. Celiprolol is a potent beta blocker on beta1-adrenoceptors and exhibits cardioselectivity both in vitro [5,7] and in vivo in the pithed rat, but shows no significant invitro alpha1-blocking action. Celiprolol differs from atenolol in that it has an intrinsic sympathomimetic activity (ISA) for beta1-adrenoceptors, which is reflected in its relative lack of negative inotropic effects in humans. In the pithed rat, celiprolol's ISA was demonstrated at much lower doses than for pindolol, even though pindolol has a similar potency to celiprolol in antagonizing the heart rate effects of isoproterenol. It was completely blocked by propranolol, indicating that celiprolol behaves like a partial agonist for beta1-adrenoceptors, whereas the ISA developed by pindolol was only partially blocked by propranolol. These data suggest a different mechanism for he development of ISA between celiprolol and pindolol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Louis WJ, McNeil JJ, Drummer OH. Labetalol and other vasodilator-beta blocking drugs. In: Doyle AE, ed. Handbook of hypertension, clinical pharmacology of antihypertensive drugs. Elsevier Press, in press, 1988.
McNeil JJ, Louis WJ. Clinical Pharmacokinetics of labetalol. Clin Pharmacokin 1984;9:157–167.
Cambridge D, Allan G, Hardy GW, et al. Pharmacological profile in vivo of a novel angiotensin converting enzyme inhibitor and beta blocker. Proc 11th Scientific Meeting of the International Society of Hypertension, Heidelberg, FRG, p. 26.
Allan G, Cambridge D, Hardy GW. BW A575C, a novel antihypertensive agent with angiotensin converting enzyme inhibition and beta blocking properties. Br J Pharmacol 1986;89:488p.
Brittain RT, Drew BM, Levy GP. The alpha-and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 1982;77:105.
Louis WJ, Drummer OH, Tung LH. Actions of dilevalol on adrenoceptors. (Proceedings of the Dilevalol Symposium, Milan, Italy) J Cardiovasc Pharmacol 1988;11:S5.
Louis WJ, McNeil JJ, Drummer OH. Labetalol and other vasodilator-beta blocking drugs. In: Doyie AE, ed. Handbook of hypertension, clinical pharmacology of antihypertensive drugs. Elsevier Press, in press, 1988.
Tung LH, Rand MJ, Louis WJ. Calcium antagonists inhibit positive chronotropic responses to alpha1-adrenoceptor activation in rat isolated atria. Eur J Pharmacol 1987;133:177.
van Rossum JM. Cumulative dose-response curves. Arch Int Pharmacodyn Ther 1963;143:299–330.
Zabarowsky J, McMahan WG, Griffin WA, et al. Computerized graphic methods of determining dissociation constants of agonists, partial agonists, and competitive antagonists in isolated smooth muscle preparations. J Pharmacol Methods 1980;4:165–178.
Mackay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol 1978;30:312–313.
Ng KKF, Duffy S, Louis WJ, et al. Everted aorta: A new method for the bioassay of vasoconstrictor substances. Proc Aust Physiol Pharmacol Soc 1975;6:158p.
Louis WJ, Drummer OH, Tung LH. Actions of dilevalol on adrenoceptors. J Cardiovasc Pharmacol, in press.
Opie LH. Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol. A Symposium: Hypertension into the Nineties. Am J Cardiol 1988;8C–13C.
Taylor SH. Celiprolol and the heart. A Symposium: Hypertension into the Nineties. Am J Cardiol 1988;34C–40C.
Dorow P. Celiprolol—Review of airways studies. A Symposium: Hypertension into the Nineties. Am J Cardiol 1988;23C–26C.
Bilski A, Robertson HH, Wade JL. A study of the relationship between cardiac-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines. Clin Exp Pharmacol Physiol 1979;6:1–9.
Herrmann JM, Bischof F, Von Heymann F, et al. Effects of celiprolol on serum lipids in systemic hypertension. A Symposium: Hypertension into the Nineties. Am J Cardiol 1988;41C–44C.
Hitzenberger G. Celiprolol, clinical dosage, efficacy and safety in asthmatic and elderly patients. Br J Clin Proc 1985;39:25–32.
Herrman JM, von Heymann F, Freischutz G, et al. Lipid profile improvement following celiprolol. New clinical perspectives beyond cardioselectivity, 1987. J Int Med Res, in press.
Castelli WP, Garrison RJ, Wilson PF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986;256:2835–2838.
Louis WJ, Howes LG, Krum H, et al. Metabolic risk factors and hypertension. JAMA 1988;13–16.
Howes LG, Louis WJ. Effects of antihypertensive drugs on cardiovascular risk factors. Clin Exp Pharmacol Physiol 1988;15:199–202.
Author information
Authors and Affiliations
Additional information
Address for correspondence and reprint requests: University of Melbourne, Clinical Pharmacology and Therapeutics Unit, Department of Medicine, Austin Hospital, Heidelberg, Victoria, 3084, Australia.
Rights and permissions
About this article
Cite this article
Louis, W.J., Drummer, O.H. & Tung, LH. Pharmacology of celiprolol. Cardiovasc Drug Ther 4 (Suppl 6), 1281–1285 (1991). https://doi.org/10.1007/BF00114234
Issue Date:
DOI: https://doi.org/10.1007/BF00114234